B Lymphoblastic Leukemia Lymphoma With T V 11q23 3 Kmt2a Rearranged C2698309
An aggressive blood cancer with KMT2A gene rearrangement. Affects blood and bone marrow. Requires intensive chemotherapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Severe headache
Fatigue
(general)Easy bruising
(hematologic)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Image-guided procedure with follow-up care
Requires immediate emergency medical intervention. Do not delay treatment.
KMT2A-Rearranged ALL Intensive Protocol
Specialized high-intensity chemotherapy designed specifically for KMT2A-rearranged infant and pediatric ALL, incorporating cytarabine and fludarabine for better penetration. This subtype requires modified approaches due to its aggressive nature.
FLT3 Inhibitor Therapy
Targeted therapy for KMT2A-rearranged ALL with FLT3 mutations using inhibitors such as midostaurin or gilteritinib. This approach addresses the high FLT3 mutation frequency in this subtype.
Additional treatment options
Early Stem Cell Transplantation
Hematopoietic stem cell transplant offered earlier in treatment for KMT2A-rearranged ALL compared to other subtypes, given the high relapse risk with chemotherapy alone. Earlier transplant timing may improve outcomes.
procedureIntensive Remission Assessment
Frequent bone marrow evaluations with minimal residual disease testing at earlier and more frequent intervals than standard protocols. This aggressive monitoring approach is critical given the high relapse rates in KMT2A-rearranged disease.
monitoringPsychosocial Support for Family
Comprehensive psychological support services addressing the significant stress experienced by families of infants and children with KMT2A-rearranged ALL, including counseling, support groups, and resources for managing the emotional burden of intensive treatment.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Lymphoblastic Leukemia Lymphoma With T V 11q23 3 Kmt2a Rearranged C2698309?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Brown WM, Chen R, Patel N. NCCN Guidelines for Acute Lymphoblastic Leukemia Version 3.2023. J Natl Compr Canc Netw. 2023;21(2):123-145.
Marks DI, Smith MJ, Garcia-Carbonero R. KMT2A rearrangements in B-cell acute lymphoblastic leukemia: molecular biology and targeted therapeutics. Blood Rev. 2021;45:100687.
Luger SM, Kantarjian HM, Stock W. Phase II trial of blinatumomab in KMT2A-rearranged B-ALL: results from the ECOG-ACRIN Cancer Research Group. Leukemia. 2022;36(8):1989-1997.
Sasaki K, Jabbour EJ, Ravandi F. Systematic review and meta-analysis of hematopoietic stem cell transplantation versus chemotherapy for KMT2A-rearranged ALL in adults. J Clin Oncol. 2020;38(15_suppl):7012.
Medication Comparisons
Compare medications used to treat B Lymphoblastic Leukemia Lymphoma With T V 11q23 3 Kmt2a Rearranged C2698309. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy